Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

Daclizumab Product Approval Information - Licensing Action

Proper name: Daclizumab
Tradename: Zenapax
Manufacturer: Hoffman-La Roche Inc, Nutley, NJ, License #0136
Revised Package Insert: Include pediatric use and update the Clinical Pharmacology, Clinical Studies, and Adverse Reactions sections of the package insert with three year posttransplant data
Approval Date: 7/29/2002
Type of submission: Biologics license application supplement

 

Approval Letter (PDF)

Label (PDF)

-
-